OLUMIANT
FDA Approves Supplemental NDA for Pfizer's Ritlecitinib Tosylate (Litfulo)
Pressure score
81
Momentum score
64
Why This Matters
Pfizer is a regulatory competitive threat because recent agency-facing activity on OLUMIANT in Immunology · JAK Inhibitor may reset approval benchmarks and timeline expectations for Lilly.
Competitive Assessment
- Threat type
- regulatory competitor
- Development stage
- Approved
- Stage gap
- Competitor is at a comparable development stage, indicating head-to-head race dynamics.
- Market share risk
- Approved competitor status elevates immediate revenue and share risk.
Strategic Action
Align with signal posture: monitor. Monitor regulatory competitor activity and refresh competitive intelligence after material readouts.
Overlap Analysis
Source Analysis
FDA Approves Supplemental NDA for Pfizer's Ritlecitinib Tosylate (Litfulo)
Dermatology · JAK Inhibitor · Regulatory Approval · This approval enhances Pfizer's position in the dermatology market, particularly in the JAK inhibitor space, potentially impacting competitors with similar products.
Source: Pfizer
View source documentRelated Signal
FDA Accepts Supplement for OLUMIANT (Baricitinib) by Eli Lilly
Open signalCompetitor Position
Competitor race
Pressure ranking for this signal's competitive set
Position: #1 of 3
Pfizer
2 competitive findings
Top program: OLUMIANT
- Pressure
- 82
- Momentum
- 64
- Threat
- regulatory competitor
- Stage
- Approved
82PfizerHighOLUMIANT·Approved
AstraZeneca
1 competitive finding
Top program: OLUMIANT
- Pressure
- 78
- Momentum
- 61
- Threat
- regulatory competitor
- Stage
- Approved
78AstraZenecaHighOLUMIANT·Approved
Roche
1 competitive finding
Top program: OLUMIANT
- Pressure
- 50
- Momentum
- 43
- Threat
- direct competitor
- Stage
- Approved
50RocheMediumOLUMIANT·Approved